LY2584702 Tosylate
10mM in DMSO
- Product Code: 201864
CAS:
1082949-68-5
| Molecular Weight: | 617.62 g./mol | Molecular Formula: | C₂₈H₂₇F₄N₇O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
LY2584702 Tosylate is a selective inhibitor of p70S6 kinase, a key enzyme involved in the PI3K/AKT/mTOR signaling pathway, which plays a critical role in cell growth, proliferation, and survival. Due to its mechanism of action, it has been investigated primarily for its potential in cancer therapy. It has shown activity in preclinical models of various solid tumors and hematologic malignancies by suppressing tumor cell proliferation and inducing apoptosis.
The compound has been studied in clinical trials for advanced or metastatic cancers, particularly where the mTOR pathway is dysregulated. Its application focuses on targeted therapy, aiming to provide efficacy with potentially fewer side effects compared to conventional chemotherapy. Research has also explored its use in combination with other anticancer agents, such as hormonal therapies or other kinase inhibitors, to overcome resistance and enhance antitumor effects.
Beyond oncology, inhibitors of the mTOR pathway have implications in inflammatory and autoimmune conditions, though LY2584702 Tosylate’s development has been mainly centered on oncology indications. Its application remains within the realm of investigational therapeutics, with ongoing evaluation to determine optimal dosing, safety, and patient selection strategies.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿6,200.00 |
+
-
|
LY2584702 Tosylate
LY2584702 Tosylate is a selective inhibitor of p70S6 kinase, a key enzyme involved in the PI3K/AKT/mTOR signaling pathway, which plays a critical role in cell growth, proliferation, and survival. Due to its mechanism of action, it has been investigated primarily for its potential in cancer therapy. It has shown activity in preclinical models of various solid tumors and hematologic malignancies by suppressing tumor cell proliferation and inducing apoptosis.
The compound has been studied in clinical trials for advanced or metastatic cancers, particularly where the mTOR pathway is dysregulated. Its application focuses on targeted therapy, aiming to provide efficacy with potentially fewer side effects compared to conventional chemotherapy. Research has also explored its use in combination with other anticancer agents, such as hormonal therapies or other kinase inhibitors, to overcome resistance and enhance antitumor effects.
Beyond oncology, inhibitors of the mTOR pathway have implications in inflammatory and autoimmune conditions, though LY2584702 Tosylate’s development has been mainly centered on oncology indications. Its application remains within the realm of investigational therapeutics, with ongoing evaluation to determine optimal dosing, safety, and patient selection strategies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :